

E. Faist J. L. Meakins  
F. W. Schildberg (Eds.)

# Host Defense Dysfunction in Trauma, Shock and Sepsis

Mechanisms and Therapeutic Approaches

With 416 Figures and 153 Tables

**Springer-Verlag**  
Berlin Heidelberg New York  
London Paris Tokyo  
Hong Kong Barcelona Budapest

# Table of Contents

## *Section 1*

### **General Aspects/Perspectives**

Progress in Trauma Care Through Understanding the Cell Biology of Injury (A. E. Baue) . . . . .	3
Trauma, Sepsis and Immune Defects (J. A. Mannick) . . . . .	15
Clinical Factors Influencing Host Defense Integrity (J. L. Meakins) . . . . .	23
The Intensive Care Unit of Tomorrow (H. J. Dieterich, K. Peter) . . . . .	31

## *Section 2*

### **Host Defense Integrity—Response and Stress**

How the Immune System Discriminates Infectious Nonself from Noninfectious Self (C. A. Janeway Jr.) . . . . .	39
Signal Transduction Mechanisms: Pathophysiologic Alterations (M. M. Sayeed) . . . . .	49
Neuroendocrine Regulation of Immune Function (J. W. Holaday, J. R. Kenner, P. F. Smith, H. U. Bryant, E. W. Bernton) . . . . .	59

**Beneficial Effects of Stress Response Blockade on Patients Undergoing Surgery**  
(H. Kehlet) . . . . . 67

**The Impact of Preexisting Disease Conditions for Host Defense Integrity in Traumatized and Critically Ill Patients**  
(N. V. Christou, J. M. Tellado) . . . . . 73

*Section 3*

**From Injury to Multiple Organ Failure:  
Sequential Steps of Host Defense Impairment**

**3.1 Shock and Ischemia**

**Oxygen Radical-Mediated Endothelial Cell Injury**  
(G. O. Till, P. A. Ward). . . . . 85

**Characteristics of Neutrophil Dysfunction**  
(G. F. Babcock, C. L. White-Owen, J. W. Alexander, G. D. Warden) . . . 95

**Endothelial Dysfunction as an Early Critical Event in Ischemia and Shock**  
(A. M. Lefer, X. Ma). . . . . 107

**Role of Oxidants, Proinflammatory Agents, and Granulocytes in the Post Ischemic Intestine**  
(P. Kubes, D. N. Granger) . . . . . 113

**Hepatic Parenchymal and Nonparenchymal Cells in Hemorrhage and Ischemia**  
(M. G. Clemens) . . . . . 127

**Acute Lung Injury Following Shock and Major Trauma**  
(G. Schlag, H. Redl) . . . . . 139

**Hemorrhage-Induced Alterations in Cell-Mediated Immune Function**  
(I. H. Chaudry, A. Ayala, D. Meldrum, W. Ertel). . . . . 149

**3.2 Intermediate Inflammatory Phase**

**Sepsis and Multiple Organ Failure: The Result of Whole Body Inflammation**  
(R. J. Goris). . . . . 161

Multiple Organ Failure (MOF), and Whole Body Inflammation  
After Multiple Trauma  
(G. Regel, H. C. Pape, F. Koopmann, J. A. Sturm). . . . . 171

Neutrophils, Cytokines, Oxygen Radicals, and Lung Injury  
(P. A. Ward, M. S. Mulligan, J. S. Warren) . . . . . 177

The Role of  $\beta_2$ - Leukocyte Integrins In Vivo  
(S. R. Sharar, N. B. Vedder, W. J. Mileski, C. L. Rice, J. M. Harlan,  
R. K. Winn). . . . . 181

The Angry Macrophage and Its Impact on Host Response Mechanisms  
(R. V. Maier) . . . . . 191

Eicosanoids, Cytokines and Altered Metabolic Control in the Evolution  
of the Posttraumatic Host Defense Failure Syndromes (Adult Respiratory  
Distress Syndrome and Multiple Organ Failure Syndrome)  
(J. H. Siegel) . . . . . 199

Diagnostic Role of New Mediators and Markers of Inflammation  
in Multiple Injured Patients  
(D. Nast-Kolb, Ch. Waydhas, M. Jochum, M. Spannagl, W. Machleidt,  
K. H. Duswald, L. Schweiberer) . . . . . 221

Intravascular Activation of Polymorphonuclear Neutrophils  
in Critically Ill Anergic Patients  
(J. M. Tellado, N. V. Christou) . . . . . 229

Mediators of Remote Lung Injury  
(T Lindsay, J. Hill, C. R. Valerie, D. Shepro, H. B. Hechtman) . . . . . 235

**3.3 Sepsis**

Immunologic Dyshomeostasis in Multiple Organ Failure:  
The Gut-Liver Axis  
(J. C. Marshall). . . . . 243

Tumor Necrosis Factor and Other Cytokines as Mediators  
of Clinical Sepsis  
(S. F. Lowry) . . . . . 253

The Protein C System in Septic Shock  
(F. B. Taylor). . . . . 263

Leukocyte-Endothelial Interactions in Trauma and Sepsis  
(H. Redl, G. Schlag, H. P. Dinges, R. Kneidinger, J. Davies) . . . . . 277

Role of Oxygen Radicals in Multiple Organ Failure  
(H. P. Friedl, O. Trentz, G. O. Till, P. A. Ward) . . . . . 287

Arachidonic Acid Metabolism in Endotoxemia and Sepsis:  
Therapeutic Approaches  
(J. A. Cook, E. Li, P. V. Halushka) . . . . . 297

*Section 4*

**Immune Mechanisms for the Control of Infection Under Physiologic  
and Stressful Conditions**

Biology and Function of Cytotoxic T-Cells  
(R. C. Bleackley) . . . . . 311

Immune Response of Heat Shock Proteins  
(S. H. E. Kaufmann) . . . . . 317

Prostaglandins Mediate the Expression of a 72-kDa Heat Shock  
Protein in Human Fibroblasts  
(A. E. Heufelder, B. E. Wenzel, R. S. Bahn) . . . . . 323

Glucocorticoid-Immune System Interactions in Injury and Sepsis  
(S. E. Calvano) . . . . . 331

Hemorrhagic Shock Inhibits Myelopoiesis Independent  
of Bacterial Translocation  
(D. H. Livingston, J. Hseih, T. Murphy, B. F. Rush Jr.) . . . . . 339

Monocyte HLA-DR Antigen Expression: Its Reproducibility  
in Asymptomatic Volunteers and Correlation with Clinical Infection  
(W. G. Cheadle, M. J. Hershman, S. R. Wellhausen, H. C. Polk Jr.) . . . . 349

Phenotypic and Functional Characteristics of Peripheral Blood  
Lymphocytes in a Defined Group of Polytrauma Patients  
(G. C. Spagnoli, M. Heberer, P. Vogelbach, R. Rosso, J. Jørgensen,  
F. Harder) . . . . . 355

Cell-Mediated Immunity During and After Cardiopulmonary Bypass  
(A. Paccagnella, S. DeAngeli, M. Mordacchini, G. Caenaro, A. Nieri,  
P. Rosi, P. Michilon, M. Calò, G. Zanardo, L. Salvador,  
C. Furlan, G. Simini) . . . . . 359

Alterations in Function and Phenotype of Monocytes from Patients with Septic Disease: Predictive Value and New Therapeutic Strategies (H. D. Volk, M. Thieme, U. Ruppe, S. Heym, W-D. Döcke, D. Manger, S. Zuckermann, A. Golosubow, B. Nieter, H. Klug, R. van Baehr) . . . . 365

Effects of Exercise on the Immune System with Special Reference to Natural Killer Cells (B .K. Pedersen) . . . . . 373

Interaction of Immune, Interferon, and Opioid Systems in Professional Athletes (E. Gotovtseva, I. Surkina, P. Uchakin, J. Shchurin, S. Pschenichkin, N. Kost, A. Zozulya, O. Ilyinsky) . . . . . 379

### *Section 5*

#### **Inflammatory Mechanisms in Traumatic and Septic Injury**

White Cells in Burn Patients (D. N. Herndon, T. C. Rutan, J. Mlakar, D. Fleming) . . . . . 385

Fibronectin Degradation: An In Vitro Model of Neutrophil Mediated Endothelial Cell Damage (K. D. Forsyth). . . . . 391

Adenosine Inhibits Postischemic Leukocyte Adherence to the Endothelium of Postcapillary Venules via A<sub>2</sub>-Receptor (D. Nolte, H. A. Lehr, K. Messmer). . . . . 399

Prostaglandin E<sub>1</sub> Inhibits the Stimulation of Neutrophils In Vitro and In Vivo and Improves Cardio-Respiratory Functions in Multiply Traumatized Patients at Risk of Adult Respiratory Distress Syndrome (A. Dwenger, M. L. Nerlich, E. Jonas, G. Schweitzer, J. A. Sturm, H. Tscherne) . . . . . 403

Production and Characterization of Peptide-Specific Monoclonal Antibodies that Recognize a Neopeptide on Hog C5a (U. Höpken, A. Strüber, M. Oppermann, M. Mohr, K. H. Mücke, H. Burchardi, O. Götze) . . . . . 411

The Oxidative Burst Reaction of Neutrophils is Reduced by the Acute Phase Serum Amyloid-A Protein (R. P. Linke, V. Bock, G. Valet, G. Rothe). . . . . 419

Interaction of Pentoxifylline and Adenosine in the Inhibition of Superoxide Anion Production of Human Polymorphonuclear Leukocytes (M. Thiel, H. Bardenheur, C. Madler, K. Peter) . . . . .	423
Adhesive Interactions of Neutrophils with Endothelial Cells (C. W. Smith, O. Abbassi, S. B. Shappell, D. C. Anderson, L. V. McIntire, T. K. Kishimoto) . . . . .	431
Endothelial Cell Stimulation by Anti-CD9 Antibodies (K. D. Forsyth). . . . .	437
Decrease in Leukotriene Synthesis from Leukocytes Isolated in Septic Patients (H. Lessire, B. Mile, M. Pfisterer, T. N. Nguyen, E. Torwesten, C. Puchstein, B. M. Peskar) . . . . .	443
Aggravation of Ischemia-Reperfusion Injury in the Striated Muscle Microcirculation by Acute Endotoxemia (H. A. Lehr, K. Kawasaki, T. J. Galla, D. Nolte, K. Messmer). . . . .	449
Selective Inhibition of Polymorphonuclear Leukocyte Oxidative Burst and CD11b/CD16 Expression by Prostaglandin E <sub>2</sub> (J. A. Lieberman, F. M. Waldman, J. K. Horn) . . . . .	453
The Role of Lysosomal Cysteine Proteinases as Markers of Macrophage Activation and as Nonspecific Mediators of Inflammation (W. Machleidt, I. Assfalg-Machleidt, A. Billing, D. Fröhlich, M. Jochum, T. Joka, D. Nast-Kolb) . . . . .	459
Endothelin Mediates a Ca <sup>2+</sup> Activation Signal in Human Monocytes (M. Huribal, D. S. Margolis, M. A. McMillen) . . . . .	465
Nitric Oxide Synthesis in Sponge Matrix Allografts Coincides with the Initiation of the Allogeneic Response (J. M. Langrehr, J. Stadler, T. R. Billiar, W. H. Schraut, R. L. Simmons, R. A. Hoffman). . . . .	471
Neutrophil Elastase Induces Lung Injury Following Lower Limb Ischemia (R. Welbourn, G. Goldman, D. Shepro, H. B. Hechtman). . . . .	477
PMN Elastase in Local Infection (K. M. Peters, K. Koberg, H. Kehren, K. W. Zilkens) . . . . .	481

Opioids from Immune Cells Interact with Receptors on Sensory Nerves to Inhibit Nociception in Inflammation  
 (C. Stein, A. H. S. Hassan, R. Przewlocki, C. Epplen, C. Gramsch, K. Peter, A. Herz) . . . . . 485

*Section 6*

**Hepatocellular Injury in Ischemia, Trauma and Sepsis**

An In Vitro Model of Hepatic Failure in Septic Shock  
 (T. Hartung, A. Wendel) . . . . . 493

Ischemia-Reperfusion Injury of the Liver: Role of Neutrophils and Xanthine Oxidase  
 (M. D. Menger, M. J. Müller, H. P. Friedl, O. Trentz, K. Messmer). . . . 499

Nitric Oxide Regulates Prostaglandin E<sub>2</sub> Release by Rat Kupffer Cells  
 (J. Stadler, B. G. Harbrecht, M. Di Silvio, R. D. Curran, M. L. Jordan, R. L. Simmons, T. R. Billiar). . . . . 505

C3a and C5a in Liver Transplantations During Bypass, Reperfusion and the Postoperative Phase  
 (M. Hartmann, L. Verner) . . . . . 511

Effect of Superoxide Dismutase on Altered Hepatic Calcium Regulation During Gramnegative Sepsis  
 (S. Rose, J. Dike, V. Bühren, O. Trentz, M. M. Sayeed) . . . . . 517

Role of Liver Macrophages (Kupffer Cells) in Bacterial Cell Wall-Induced Hepatic Inflammation  
 (T. Kossmann, C. Manthey, J. B. Allen, C. Morganti-Kossmann, K. Ohura, S. E. Mergenhagen, S. M. Wahl) . . . . . 523

Tumor Necrosis Factor Alpha Inhibits Hepatocyte Mitochondrial Respiration and Induces Release of Cytoplasmic Enzymes  
 (J. Stadler, B. G. Bentz, J. M. Langrehr, R. D. Curran, T. R. Billiar, B. G. Harbrecht, R. L. Simmons) . . . . . 527

Modulation of Hepatic Mitochondrial Fat Oxidation and Hepatic Gene Transcription by Tumor Necrosis Factor  
 (R. A. Barke, P. S. Brady, L. J. Brady) . . . . . 531



Increased Leukocyte Adhesion in Liver Sinusoids Following Superior Mesenteric Artery Occlusion in the Rat  
(V. Bühren, B. Maier, R. Hower, M. D. Menger, I. Marzi) . . . . . 539

*Section 7*

**Cytokines and Modulation of Cytokine Action**

Gene Knockout: New Approach to the Physiology of Cytokines  
(F. F. Csaikl, U. N. Csaikl, S. K. Durum) . . . . . 547

The Role of Interleukin-1 and Other Macrophage-Derived Cytokines in Macrophage-T-Cell Interactions  
(L. S. Davis, P. E. Lipsky) . . . . . 557

Interleukin-1-Induced Hypotension and the Effect of an Interleukin-1 Receptor Antagonist  
(C. A. Dinarello) . . . . . 571

Interleukin-8 (Neutrophil-Activating Peptide-1) and Related Chemotactic Cytokines  
(M. Baggiolini) . . . . . 577

Cellular and Molecular Mechanisms that Regulate the Production of Interleukin-8: The Potential Role of Chemotactic Cytokines in Acute Respiratory Distress Syndrome and Multiple Organ Failure  
(S. L. Kunkel, S. W. Chensue, T. J. Standiford, R. M. Strieter) . . . . . 583

Generation and Properties of Neutrophil-Activating Peptide 2 (NAP-2)  
(A. Walz, F. Meloni, R. Zwahlen, I. Clark-Lewis, B. Car) . . . . . 593

Soluble and Cell Surface Receptors for Tumor Necrosis Factor  
(H. Engelmann, D. Aderka, Y. Nophar, O. Kemper, C. Brakebusch, H. Holtmann, D. Wallach) . . . . . 599

Regulation of Cytokine Synthesis Through Cyclic Nucleotides  
(S. Endres, H. J. Fülle, B. Sinha, D. Stoll, R. Gerzer) . . . . . 609

Removal of Circulating Cytokines by Hemodialysis Membranes In Vitro  
(G. Lonnemann, R. Schindler, C. A. Dinarello, K. M. Koch) . . . . . 613

Modulation of Monokine Production In Vitro by Human Intravenous Immunoglobulin  
(J. P. Andersson, S. Nagy, U. G. Andersson) . . . . . 625

Transforming Growth Factor  $\beta$ 1 Upregulates the Interleukin-2 Receptor  $\alpha$  Promoter  
(C. S. Cocanour, F. M. Orson, D. Thomas, S. Rich) . . . . . 629

*Section 8*

**Cytokines in Acute Phase States and Trauma**

Interactions of Immunopathological Mediators (Tumor Necrosis Factor- $\alpha$ , - $\beta$ , Prostaglandin E<sub>2</sub>) in Traumatized Individuals  
(C. L. Miller-Graziano, G. Szabo, K. Kodys, B. Mehta). . . . . 637

In Vitro Production and Secretion of Interleukin-1 by Human Monocytes After Surgical Trauma  
(M. L. Vuotto, E. Bresciano, D. Mancino, M. T. Ielpo, M. R. Mosti, G. De Martino, A. Barbarisi) . . . . . 651

The Biological Characteristics of Cytokines and Their Interactions with Prostaglandins Following Hemorrhagic Shock  
(W. Ertel, E. Faist, I. H. Chaudry) . . . . . 655

The Response of Interleukin-1 and Interleukin-6 in Patients Undergoing Major Surgery  
(R. J. Baigrie, P. M. Lamont, M. J. Dallman, P. J. Morris) . . . . . 665

Possible Role of Cytokines in the Stress Response of the Hypothalamo-Pituitary-Adrenal Axis During Upper Abdominal Surgery  
(Y. Naito, S. Tamai, K. Shingu, K. Shindo, T. Shichino, T. Matsui, O. Ebisui, J. Fukata, K. Yone, K. Mori) . . . . . 673

The Synthesis of Stress Proteins in Cultured Cardiac Myocytes Is Induced by the Interleukins and Tumor Necrosis Factor  
(I. Löw-Friedrich, D. Weisensee, P. Mitrou, W. Schoeppe) . . . . . 677

Effects of Tumor Necrosis Factor on the Hypothalamic-Pituitary-Adrenal Axis  
(K. Mealy, B. G. Robinson, J. A. Majzoub, D. W. Wilmore) . . . . . 681

Interleukin-2-Modulated Cytokine Secretion in Thermally Injured Patients  
(J. Teodorczyk-Injeyan, B. Sparkes, W. Peters) . . . . . 687

Cytokine Treatment of Radiation-Induced Hemopoietic Suppression:  
Results of Interleukin-6 and Granulocyte Colony-Stimulating Factor  
in a Murine Radiation Model  
(M. L. Patchen, T. J. Mac Vittie, B. D. Solberg, R. Fischer,  
L. M. Souza) . . . . . 693

Circulating Tumor Necrosis Factor in Active Inflammatory Bowel Disease  
(K. R. Gardiner, M. I. Halliday, F. Lloyd, S. Stephens, B. J. Rowlands) . 699

Interleukin-1 and Tumor Necrosis Factor- $\alpha$  Suppress Hypoxia-Induced  
Production of Erythropoietin In Vitro  
(M. Wolff, W. Jelkmann, J. Fandrey) . . . . . 705

Neopterin, Interferon- $\gamma$ , and Immunodeficiency States  
(D. Fuchs, A. Hausen, G. Reibnegger, G. Weiss, E. R. Werner,  
G. Werner-Felmayer, H. Wachter) . . . . . 715

Systemic Cytokine Response to Strenuous Exercise  
(H. Northoff, M. W. Baumstark, W. A. Flegel, A. Berg) . . . . . 719

*Section 9*

**The Mediator Role of TNF in Sepsis**

Activation of Neutrophils by Tumor Necrosis Factor- $\alpha$  During Sepsis  
(G. Rothe, W. Kellermann, J. Briegel, B. Schaerer, G. Valet) . . . . . 727

Distinct Subpopulations of Human Peripheral Blood Monocytes  
Characterized by Absence of the CD14 Surface Marker, and  
Distinguished by High or Low Intracellular Glutathione  
(R. L. Rabin, F. J. Staal, M. Roederer, M. M. Beiber, L. A. Herzenberg,  
N. H. Teng) . . . . . 737

The Role of Endotoxins in Burns: Anomalies in Cytokine Regulation  
of Immunity  
(R. A. Winchurch, D. Zhou, A. M. Munster) . . . . . 743

Role of Tumor Necrosis Factor on *Pseudomonas Aeruginosa* Infection  
and on Antitumor Activity in Relation to Arachidonic Cascade  
(N. Satomi, A. Sakurai, R. Haranaka, K. Haranaka). . . . . 751

Survival from Cecal Ligation and Puncture and the Formation of Fibrous Adhesions in the Peritoneal Cavity Depend on Endogenous Tumor Necrosis Factor  
(B. Echtenacher, W. Falk, D. N. Männel, P. H. Krammer) . . . . . 755

The Cellular Mechanisms of Tumor Necrosis Factor-Induced Mortality: A Possible Role for Platelet Activating Factor and/or the Eicosanoids  
(J. M. Moore, M. Hubbard, M. Earnest, P. Williams, A. DiSimone, N. Abumrad, J. R. Fletcher) . . . . . 759

*Section 10*

**Endotoxin—Mechanisms of Action and Protection from Shock**

Molecular Mechanisms of Lipopolysaccharide-Induced Cytokine Production by Monocytes  
(R. R. Schumann, J. C. Mathison, P. S. Tobias, R. J. Ulevitch). . . . . 767

Natural Endotoxic Shock Protection by Soluble CD14  
(C. Schütt, C. Krüger, W. Schönfeld, U. Grunwald, T. Schilling). . . . . 773

Use of Monophosphoryl Lipid A as a Prohylactic for Sepsis and Shock  
(J. A. Rudbach, J. T. Ulrich, K. B. von Eschen, D. Beatty) . . . . . 779

Hemodynamic and Pulmonary Response to Treatment with On-Line Adsorption on Polymyxin B During Endotoxemia in Pigs  
(B. Strittmatter, W. Schneider, K. Massarrat, A. Eckhardt, B. U. von Specht) . . . . . 783

Apolipoprotein A-I Enriched Lipoprotein Attenuates Tumor Necrosis Factor Production and Shock in an Anesthetized Rabbit Endotoxemia Model  
(A. P. Hubsch, J. E. Doran, P. G. Lerch, G. Hodler, J. J. Morgenthaler, H.-J. Heiniger) . . . . . 789

*Escherichia Coli*-Induced Septic Shock in the Baboon: An Animal Model for the Evaluation of Neutralising Monoclonal Antibodies to Phospholipase A<sub>2</sub>  
(R. Buchta, J-A, Green, G. M. Smith, C. Gabelish, D. Cairns, C. Salom, M. Conte, P. Mackie, R. Sublett, F. B. Taylor, I. A. Rajkovic, K. F. Scott). . . . . 792

Leukotriene Inhibitor and Antagonist Prevent Endotoxin Lethality  
in Carrageenan-Pretreated Mice  
(O. Masanori, K. Masayuki, Y. Shin-Ichi, M. Yasuo, A. Shigematsu) . . . 799

Effect of Type-Specific Antiserum on the Pulmonary Hypertensive  
Response to Group B *Streptococcus* in Piglets  
(J. B. Philips, M. Chwe, J. X. Li, B. M. Gray, D. G. Pritchard,  
J. R. Oliver, K. Grantham, W. Mena) . . . . . 803

Detection of IgE Reactive with Lipopolysaccharide in Plasma of  
Traumatically Injured Patients  
(J. T. Di Piro, R. G. Hamilton, T. R. Howdieshell, D. Callaway,  
N. F. Adkinson) . . . . . 807

Altered Guanine Nucleotide Protein Function: Potential Role in  
Endotoxin Tolerance  
(K. Coffee, P. V. Halushka, W. C. Wise, J. A. Cook). . . . . 811

*Section 11*

**Clinical Aspects of Multiple Organ Failure**

The Pattern of Organ Failure Following Severe  
Trauma—A Postmortem Study  
(H. C. Pape, G. Regel, Kleemann, J. A. Sturm, H. Tscherne) . . . . . 823

Hypertonic Volume Therapy: A Feasible Regimen to Contribute  
to the Prevention of Multiple Organ Failure?  
(U. Kreimeier, L. Frey, A. Pacheco, K. Messmer). . . . . 831

A New Sepsis Scale for Burns: Correlation with Endotoxin  
and Host Response  
(A. M. Munster, M. Meek, R. A. Winchurch, C. Dickerson) . . . . . 843

Multiple Organ Failure: Clinical Characteristics of Gut-Origin Septic States  
(J. R. Border) . . . . . 851

Intraperitoneal Infections and Multiple Organ Failure  
(T. Hau). . . . . 857

The Role of Empirical Laparotomy in the Management of Sepsis  
and Multisystem Organ Failure  
(H. C. Polk, P. Burgess, W. G. Cheadle) . . . . . 863

Management of the Wound as Therapy for Multiple Organ Failure  
(L. Flint). . . . . 867

Aggressive Enteral Nutrition Reduces Sepsis in the Hypercatabolic  
Injured Patient  
(E. E. Moore, F. A. Moore) . . . . . 871

Clinical-Mediator Correlations of Multiple Organ Failure and  
Preventive/Therapeutic Strategies: To Block Stimulate, or Replace?  
That is the Question  
(A. E. Baue). . . . . 881

*Section 12*

**The Pathophysiologic Impact of Bacterial Translocation  
and Strategies for Its Prevention**

Bacterial Translocation Following Major Thermal Injury in Rats, Sheep,  
and Mini-Pigs  
(D. N. Herndon, S. T. Zeigler, T. C. Rutan, R. Saydjari, S. E. Morris,  
G. I. Beerhuizen, R. Tokyay, C. M. Townsend) . . . . . 893

Does Early Portal Bacteremia/Endotoxemia Prime for Postinjury  
Multiple Organ Failure?  
(F. A. Moore, E. E. Moore, R. S. Poggetti, O. J. McAnena) . . . . . 899

Prevention of Bacterial Translocation with Early Enteral Feeding—A  
Feasible Approach?  
(J. W. Alexander). . . . . 903

Gut-Derived Infectious-Toxic Shock Syndrome: Therapeutic Chances  
with Polyspecific Immunoglobulins  
(H. Cottier, A. Hässig, R. Kraft). . . . . 911

Maintenance of Gastrointestinal Integrity After Burn Injury with  
Specific Dietary Supplementation and Epidermal Growth Factor  
(R. L. Zapata-Sirvent, J. F. Hansbrough, M. C. Cox, P. Wolf). . . . . 917

Selective Decontamination of the Digestive Tract: Open Questions  
and Controversies  
(L. L. Dever, W. G. Johanson Jr.). . . . . 925

Selective Decontamination of the Digestive Tract (SDD): Review of Available Clinical Studies (C. P. Stoutenbeek, H. K. van Saene). . . . . 931

Nonselective Gut Decontamination for Avoidance of Bacterial Translocation in Shock (J. Brand, A. Ekkernkamp, A. Helbig, G. Muhr) . . . . . 939

*Section 13*

**Antibiotic Interactions with Host Defenses**

Antibiotics and Phagocytic Cell Function: A Critical Review (P. van der Auwera, M. Bonnet, M. Husson, F. Jacobs). . . . . 945

Interaction of Antibiotics with the Phagocyte Oxidative Burst (M. T. Labro, J. El Benno). . . . . 953

Intraphagocytic Cell Penetration and Intracellular Bioactivity of Antibiotics (A. Pascual). . . . . 965

Extraphagocytic Killing of Bacteria in the Presence of Antibiotics (P. J. van den Broek) . . . . . 971

Cell Wall Inhibitors and Bacterial Susceptibility to Phagocytosis (A. M. Cuffini, N. A. Carlone, V. Tullio, G. Cavallo). . . . . 979

Protein Synthesis Inhibitors and Bacterial Susceptibility to Phagocytosis (C. G. Gemmell) . . . . . 987

*Section 14*

**The Role of Nutrition in Host Defense**

Augmentation of Host Defense Reactivity with Special Nutrients (J. W. Alexander). . . . . 995

The Role of Structured Lipids in Host Defense Interactions (R. A. Forse, G. L. Blackburn, B. R. Bistrrian). . . . . 1003

Manipulation of Cytokine Synthesis Through Dietary Lipids  
(S. Endres, S. N. Meydani, C. A. Dinarello) . . . . . 1013

Dietary Fish Oil Prevents Postischemic Leukocyte/Endothelium  
Interaction Through Inhibition of Leukotriene Biosynthesis  
(H. A. Lehr, D. Nolte, C. Hübner, K. Messmer) . . . . . 1017

Dietary Requirement for Preformed Purine and Pyrimidine Bases  
for Intact Function of Cellular Immune Response: A Review  
(L. G. Kabbash, A. R. Forse). . . . . 1023

Relationship of Plasma Acute-Phase Protein to Amino Acid Levels  
During High-Dose Branched Chain Amino Acid Support in Sepsis  
(C. Chiarla, I. Giovannini, J. H. Siegel, M. Castagneto) . . . . . 1029

*Section 15*

**New Insights into the Mechanisms of Wound Healing**

Wound Management and the Stress Response  
(D. N. Herndon, R. L. Rutan, T. C. Rutan, J. M. Mlakar) . . . . . 1037

The Role of the Wound in Posttraumatic Immune Dysfunction  
(M. C. Regan, A. Barbul) . . . . . 1043

The Role of Growth Factors in the Regulation of Wound Repair  
(D. R. Knighton, V. D. Fiegel, G. D. Phillips). . . . . 1051

An Adverse Wound Environment Reduces Leukocyte Phagocytosis  
and Protein Synthesis  
(B. R. Moelleken, S. J. Mathes, A. Amerhauser, D. C. Price,  
T. K. Hunt) . . . . . 1065

Basic Fibroblast Growth Factor Inhibits the Release of Oxygen Radicals  
by Human Granulocytes  
(W. Macheiner, C. Oismüller, W. Pohl, M. Micksche) . . . . . 1079

The Influence of Liver Regeneration on Skin Wound Healing and  
Lymphocyte Growth Features  
(N. Žarković, I. Stipančić, M. Hrzenjak, Z. Ilić, S. Kiš, I. Vucković,  
M. Jurin) . . . . . 1085



*Section 16*

**Therapeutic Immunomodulatory Approaches: Prevention**

- Therapy of Secondary T-Cell Immunodeficiencies with Biological Substances and Drugs: An Update  
(J. W. Hadden, E. M. Hadden). . . . . 1097
- Progress in Antiinfective Perioperative Immunomodulatory Therapy with Simultaneous Administration of Blocking and Enhancing Agents  
(E. Faist, A. Markewitz, S. Endres, D. Fuchs, L. Hültner, S. Lang) . . . 1109
- Effect of Immunomodulation of Skin Test Reactivity Following Trauma  
(W. Browder, D. Williams, G. Olivero, P. Mao, A. Franchello, F. Enrichens) . . . . . 1131
- Therapeutic Use of Cytokines: Animal Models  
(M. L. Rodrick, N. M. Moss, D. B. Gough, P. G. Horgan, B. M. Crowley, M. G. O'Riordain, R. G. Molloy, J. A. Mannick). . . . . 1135
- The Rationale for Gamma-Interferon Administration in Trauma Patients  
(H. C. Polk, Jr., S. Galandiuk, G. Sonnenfled, W. G. Cheadle). . . . . 1145
- Immunomodulators of the Thermal Injury Response  
(J. M. Mlakar, J. P. Waymack) . . . . . 1153

*Section 17*

**Endotoxin Neutralization with IV-Immunoglobulins and Monoclonal Antiendotoxin Antibodies**

- Antiendotoxic Therapy with Polyclonal and Polyvalent Immunoglobulins: In Vitro and In Vivo Studies  
(D. Berger, S. Schleich, M. Seidelmann, H. G. Beger) . . . . . 1163
- The Use of Polyvalent Immunoglobulin G in Patients with Sepsis and Multiple Organ Failure  
(G. Pilz, K. Werdan). . . . . 1175
- Clinical Effects of Immunoglobulin Administration in Patients with Major Burn Injury  
(A. M. Munster) . . . . . 1187

Treatment of Gram-Negative Septic Toxic Diseases with an Immunoglobulin Preparation Containing IgG, IgM, and IgA: A Prospective Randomized Clinical Trial  
 (I. Schedel, U. Dreikhausen, B. Nentwig, M. Höckenschneider, D. Rauthmann, S. Balikcioglu, R. Coldewey, H. Deicher) . . . . . 1193

Immunotherapeutic Strategies for Passive Immunization Against *Pseudomonas aeruginosa*  
 (L. Saravolatz, J. Kilborn, J. Pennington) . . . . . 1205

Binding Characteristics of the Antiendotoxin Antibody Xomen-E5 to Bacterial Whole-Cell Antigens  
 (K. J. Gorelick, D. M. Wood, J. B. Parent, E. Lim, K. D. Knebel, D. M. Fishwild, D. T. Reardan, P. W. Trown, P. J. Conlon) . . . . . 1211

Immunotherapy with Human Antiendotoxin Antibodies in the Treatment of Gram-Negative Sepsis: Practical Considerations  
 (C. H. Wortel) . . . . . 1219

The Use of Antibody Specificity and Affinity in Determining the Protectiveness of Human Monoclonal Antibodies Against Fatal Infections with Nosocomial Gram-Negative Bacteria  
 (U. Bruderer, A. B. Lang, B. Byl, A. Crusiaux, J. Deviere). . . . . 1223

*Section 18*

**Interventional Strategies in the Therapy of Septic Shock**

Potential Benefits of Platelet Activating Factor Receptor Antagonists in Endotoxemia/Sepsis  
 (J. R. Fletcher, J. A. Moore, A. G. DiSimone, N. Abumerad, P. Williams, J. Pollard, J. Collins, E. Graves) . . . . . 1229

Phospholipase A<sub>2</sub>: A New Target for Monoclonal Antibody Therapy in Sepsis  
 (K. F. Scott, G. M. Smith, J. A. Green, C. Salom, C. Gabelish, D. Cairns, A. Tseng, P. Mackie, R. Buchta, R. Lee, I. A. Rajkovic) . . . 1237

Administration of Antiadhesion Molecules: A Feasible Approach?  
 (R. K. Winn, S. R. Sharar, W. J. Mileski, C. L. Rice, J. M. Harlan) . . . 1243

Local Administration of Interleukin-2 Protects Mice from Lethal Intra-Abdominal Bacterial Sepsis  
 (R. Richards, D. R. Green) . . . . . 1251

Murine Intraabdominal Abscess: Immune Modulation with Interferon- $\gamma$   
(S. Galandiuk, S. Appel, J. D. Pietsch, W. G. Cheadle, H. C. Polk, Jr.) . 1257

Acute Resuscitation and Antioxidant Therapy  
(B. E. Hedlund, P. E. Hallaway) . . . . . 1263

Clinical Indications for the Administration of Oxygen Radical Scavengers  
(J. Hill, T. Lindsay, C. R. Valeri, D. Shepro, H. B. Hechtman) . . . . . 1271

First Experiences with Recombinant Human Superoxide Dismutase  
Therapy in Polytraumatized Patients  
(I. Marzi, V. Bühren, A. Schüttler, O. Trentz) . . . . . 1279

**Subject Index** . . . . . 1285

# Diagnostic Role of New Mediators and Markers of Inflammation in Multiple Injured Patients

D. Nast-Kolb<sup>1</sup>, C. Waydhas<sup>1</sup>, M. Jochum<sup>2</sup>, M. Spannagl<sup>3</sup>, W. Machleidt<sup>4</sup>, K.H. Duswald<sup>1</sup>, and L. Schweiberer<sup>1</sup>

## Introduction

The major cause of late death after severe blunt trauma is (multiple) organ failure (OF), which is a direct consequence of mediators released during primary tissue damage and circulatory shock. To further elucidate the role of inflammatory mediators in the development of OF we performed a prospective study in severely injured patients. In a second step we examined the early prognostic value of objective biochemical markers for death and the development of OF compared to the Injury Severity Score (ISS).

## Patients and Methods

In the period 1986–1989, traumatized patients arriving at our emergency room were included in the prospective study if all of the following criteria were met: (a) severe injuries of at least two body regions (head/brain, thorax, abdomen, skeletal system) or three major fractures, (b) age between 16 and 70 years, and (c) less than 6 h between accident and admission to the emergency department. A total of 69 primary surviving patients entered the study. The mean ISS was 36 (range, 13–66). Between days 4 and 28, 11 patients died (median survival time, 19, days). Of survivors, 29 suffered from OF, and 29 had an event-free recovery. Three groups were formed: group 1, lethal OF ( $n = 11$ ); group 2, reversible OF ( $n = 29$ ); group 3, no OF ( $n = 29$ ).

Laboratory testing and recording of clinical data was started within 30 min after arrival of the patient in the emergency department and continued on a 6-h basis. After 48 h the interval was extended to 24 h for a period of 14 days. After 2

---

<sup>1</sup> Chirurgische Klinik und Poliklinik, Klinikum Innenstadt der Universität München, Nußbaumstr. 20, 8000 Munich 2, FRG

<sup>2</sup> Abteilung für Klinische Chemie und Klinische Biochemie, Chirurgische Klinik und Poliklinik, Klinikum der Universität München, Nußbaumstr. 20, 8000 Munich 2, FRG

<sup>3</sup> Medizinische Klinik, Klinikum Innenstadt der Universität München, Nußbaumstr. 20, 8000 Munich 2, FRG

<sup>4</sup> Institut für Physiologische Chemie, Physikalische Biochemie und Zellbiologie der Universität München, Goethestr. 3, 8000 Munich 2, FRG

weeks the clinical course was recorded until either transfer to a general ward or death. The biochemical markers studies are shown in the Fig. 1.

The following definitions were used:

*Respiratory failure*: need of mechanical ventilation and  $pO_2/FiO_2 \leq 280$  or positive end-expiratory pressure  $\geq 8$  mmHg for at least 24 h

*Renal failure*: creatinine  $\geq 177 \mu\text{mol/l}$  for at least 48 h

*Liver failure*: bilirubin  $\geq 51 \mu\text{mol/l}$  for at least 48 h

*Disseminated intravascular coagulation*: (a) thrombocytes  $\leq 100 \times 10^9/l$  or fall of  $\geq 30\%$  in 24 h, (b) partial thromboplastin time  $\geq 50$  s for 24 h, (c) 22 reptilase time  $\geq 22$  s for 24 h




Fig. 1. Biochemical markers in traumatic hemorrhagic shock

Table 1. Complications (n = 69)

	Incidence (n)
Multiple organ failure	29
Sepsis	20
Respiratory Failure	42
Adult respiratory distress syndrome	17
Liver failure	42
Renal failure	17
Gastrointestinal failure	7
Disseminated intravascular coagulation	7
No complications	32

*GI failure:* endoscopically confirmed ulceration with bleeding, acalculous cholecystitis

*MultipleOF:* Failure of two or more organ systems at the same time

The complications of the 69 patients are shown in Table 1.

Statistical testing was done with the non parametric Wilcoxon test for two samples. Differences were considered significant with  $p$  values below 0.05.





Fig. 2. Lactate, PMN elastase, and cathepsin B in groups 1 (\*), 2 (O), and 3 (+)

## Results

The release of mediators and indicators of inflammatory reactions in the three outcome groups is displayed in Figs. 2–4 for those markers which showed clinical relevance. The following differences proved to be significant. A higher



**Fig. 3.** C-reactive protein, DD fragment, and neopterin in groups 1 (\*), 2 (O), and 3 (+)

accumulation of lactate (Fig. 3) was observed in non survivors (group 1) compared to survivors with organ failure (group 2) throughout 14 days of observation. The level of polymorphonuclear leukocyte (PMN) elastase (Fig. 2) showed a highly significant difference in groups 1 and 2 versus group 3 throughout the whole observation period and in group 1 versus group 2 after the




Fig. 4. Antithrombin III, prothrombin, and t-PA in groups 1 (\*), 2 (O), and 3 (+)



3rd day. Cathepsin B (Fig. 2) distinguished patients with OF (groups 1 and 2) from those with uneventful recovery (group 3) within the first 4 days. The production of C-reactive protein; (CRP; Fig 3) was different among all outcome groups starting on the 3rd day after trauma. The D-dimer fragment (Fig. 3) of group 3 differed from that of groups 1 and 2 at arrival, and the levels of all three groups differed between days 3 and 5. Neopterin (Fig. 3) was higher in group 1 (nonsurvivors) compared to survivors (groups 2 and 3) from the 2nd day onwards and between groups 2 versus 3 after the 4th posttraumatic day. Antithrombin III (Fig. 4) showed a lower inhibitory activity in groups 1 and 2 versus group 3 all the time and between groups 1 and 2 (nonsurvivors versus survivors with OF) after the 1st week. At arrival, prothrombin and tissue plasminogen activator (t-PA; Fig 4) distinguished between patients developing OF (groups 1 and 2) and those having an uneventful recovery (group 3). In the 2nd week prothrombin differed between survivors and nonsurvivors.

As OF often started on the 1 day, prediction of later OF was possible at hospital arrival, whereas a lethal outcome could be predicted within the first 3 days. The demonstrated mediators showed a reasonable accuracy in predicting OF and death with a higher validity than the ISS Table 2. The combination of the four factors with prognostic value for death (PMN elastase, CRP,

**Table 2.** Prognostic value for lethal outcome at hospital arrival<sup>a</sup> and at day 4

	ACC	Sens	Spec	PPV	NPV
Lactate <sup>a</sup> (> 45 mg/dl)	88%	60%	93%	60%	93%
Elastase (> 500 ng/ml)	90%	73%	93%	67%	95%
CRP (> 20 mg/dl)	88%	67%	98%	86%	95%
Neopterin (> nmol/l)	86%	75%	93%	67%	95%
ISS (> 50)	80%	36%	88%	36%	88%

ACC, Accuracy; Sens, sensitivity; Spec, specificity; PPV, positive, predictive value; NPV, negative predictive value.

<sup>a</sup>Prognostic value at hospital arrival for lactate only.

**Table 3.** Prognostic value for organ failure at hospital arrival

	ACC	Sens	Spec	PPV	NPV
Cathepsin B (> 190 U/l)	90%	63%	86%	86%	62%
Elastase (> 200 ng/ml)	67%	84%	42%	68%	65%
Antithrombin III (< 80%)	66%	71%	58%	71%	58%
Prothrombin (< 70%)	61%	71%	60%	73%	58%
D-dimer fragment (> 12 000 ng/ml)	61%	62%	61%	70%	52%
t-PA (> 8 ng/ml)	57%	62%	54%	68%	48%
ISS (> 30)	61%	70%	48%	65%	54%

ACC, Accuracy; Sens, sensitivity; Spec, specificity; PPV, positive, predictive value; NPV, negative predictive value.

**Table 4.** Prognostic value of the combination of four parameters for lethal outcome: elastase, CRP, neopterin, lactate

	(minimum of pathological factors)		
	3	2	1
Sensitivity	53%	73%	93%
Specificity	99%	87%	67%
PPV	89%	50%	34%
NPV	92%	95%	98%
Accuracy	92%	85%	61%

PPV, Positive predictive value; NPV, negative predictive value.

neopterin, lactate) further improved the accuracy of prediction. More than three pathological results showed a very high risk of death; normal release of all mediators indicated survival (Table 3, 4).

## Summary

Biochemical mediators showed a significant difference between traumatized patients with lethal, reversible, and no organ failure. These objective parameters of inflammation might give a more accurate description of injury severity and allow a better estimation of risk for OF than many trauma severity scores.